Denali Therapeutics (NASDAQ:DNLI) Shares Up 9.3% – Still a Buy?

Posted by George Bondi on Jun 17th, 2026

Denali Therapeutics Inc. (NASDAQ:DNLI – Get Free Report)’s stock price shot up 9.3% on Wednesday . The company traded as high as $23.66 and last traded at $23.97. 474,482 shares were traded during mid-day trading, a decline of 73% from the average session volume of 1,745,651 shares. The stock had previously closed at $21.93.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on DNLI. Wolfe Research started coverage on Denali Therapeutics in a research report on Monday, February 23rd. They issued a “peer perform” rating for the company. Stifel Nicolaus raised their price target on Denali Therapeutics from $34.00 to $41.00 and gave the stock a “buy” rating in a research note on Thursday, March 26th. The Goldman Sachs Group raised their price target on Denali Therapeutics from $35.00 to $40.00 and gave the stock a “buy” rating in a research note on Thursday, March 26th. Morgan Stanley cut their price target on Denali Therapeutics from $40.00 to $35.00 and set an “overweight” rating for the company in a research note on Friday, May 22nd. Finally, Leerink Partners cut their price target on Denali Therapeutics from $40.00 to $35.00 and set an “outperform” rating for the company in a research note on Wednesday, April 22nd. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $34.25.

Get Our Latest Stock Report on DNLI

Denali Therapeutics Price Performance

The stock has a 50 day moving average of $19.86 and a two-hundred day moving average of $19.49. The company has a debt-to-equity ratio of 0.01, a quick ratio of 9.28 and a current ratio of 9.28. The firm has a market capitalization of $3.79 billion, a P/E ratio of -8.28 and a beta of 1.03.

Denali Therapeutics (NASDAQ:DNLI – Get Free Report) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.69) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.73) by $0.04. During the same period in the prior year, the company earned ($0.78) earnings per share. Sell-side analysts predict that Denali Therapeutics Inc. will post -2.77 earnings per share for the current fiscal year.

Institutional Trading of Denali Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Headlands Technologies LLC acquired a new stake in shares of Denali Therapeutics during the 2nd quarter worth approximately $26,000. Johnson Financial Group Inc. acquired a new stake in Denali Therapeutics in the 3rd quarter valued at $29,000. State of Wyoming acquired a new stake in Denali Therapeutics in the 2nd quarter valued at $29,000. Fifth Third Bancorp acquired a new stake in Denali Therapeutics in the 1st quarter valued at $55,000. Finally, Aster Capital Management DIFC Ltd acquired a new stake in Denali Therapeutics in the 4th quarter valued at $57,000. Institutional investors and hedge funds own 92.92% of the company’s stock.

About Denali Therapeutics

(Get Free Report)

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.